5913 Results

People

  1. Ladanyi
    Ladanyi
  2. Solit
    Solit
  3. Levine
    Levine
  4. Berger
    Berger
  5. Schultz
    Schultz
  6. Arcila
    Arcila
  7. Hakimi
    Hakimi
  8. Chandarlapaty
    Chandarlapaty
  9. Zehir
    Zehir
  10. Mellinghoff
    Mellinghoff

Groups

  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)
  7. Sloan Kettering Institute Postdocs (1984)
  8. Hematologic Malignancies, Division of (1879)
  9. Center for Hematologic Malignancies (1845)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (1735)
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (2984)
  2. Meeting Abstract (2526)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (41)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)

More Groups

People
  1. Marc Ladanyi (1326)
  2. David Solit (779)
  3. Ross Levine (774)
  4. Michael Berger (765)
  5. Nikolaus Schultz (486)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (119)
  2. 2024 (359)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (636)
  2. Blood (495)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (268)
  6. Laboratory Investigation (262)

More Publications

Publishers
  1. American Association for Cancer Research (871)
  2. Nature Publishing Group (757)
  3. American Society of Clinical Oncology (702)
  4. American Society of Hematology (541)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5913)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Isocitrate dehydrogenase mutant grade II and III glial neoplasms
    Review

    Mellinghoff, I. K.; Chang, S. M.; Jaeckle, K. A.; van den Bent, M.
    Hematology/Oncology Clinics of North America (2022)

    Fulltext@MSK | Save
  • Local control and survival after induction chemotherapy and ablative radiation versus resection for pancreatic ductal adenocarcinoma with vascular involvement
    Journal Article

    Jolissaint, J. S.; Reyngold, M.; Bassmann, J.; Seier, K. P.; Gönen, M.; Varghese, A. M.; Yu, K. H.; Park, W.; O'Reilly, E. M.; Balachandran, V. P.; more...
    Annals of Surgery (2021)

    Fulltext@MSK | Save
  • Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34(+)-selected allogeneic transplantation
    Journal Article

    Cho, C.; Hilden, P.; Avecilla, S. T.; Barker, J. N.; Castro-Malaspina, H.; Giralt, S. A.; Gyurkocza, B.; Jakubowski, A. A.; Maloy, M. A.; O'Reilly, R. J.; more...
    Advances in Cell and Gene Therapy (2021)

    Fulltext@MSK | Save
  • ERK2 substrate binding domains perform opposing roles in pathogenesis of a JAK2V617F-driven myeloproliferative neoplasm
    Meeting Abstract

    Truong, B.; Zhang, Y.; Fahl, S.; Qcai, K.; Martinez, E.; Al-Saleem, E.; Gong, Y.; Liebermann, D.; Soboloff, J.; Dunbrack, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Gilteritinib (GILT) monotherapy with addition of decitabine (DEC) in non-responders in older newly diagnosed (ND) FLT3 mutated acute myeloid leukemia (AML) patients having high and low variant allele frequency (VAF): A phase 2/1b sub-study of the Beat AML Master Trial
    Meeting Abstract

    Traer, E.; Huang, Y.; Mims, A. S.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; Schiller, G. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Timing and immune status after cellular therapies predict response to COVID-19 vaccines
    Meeting Abstract

    Tamari, R.; Politikos, I.; Knorr, D.; Vardhana, S.; Young, J.; Marcello, L.; Doddi, S.; Devlin, S. M.; Ramanathan, L.; Pessin, M. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) in combination with azacitidine (AZA) in newly diagnosed (ND) older patients with IDH1 R132-mutated acute myeloid leukemia (AML) induces high response rates: A phase 2 sub-study of the beat AML master trial
    Meeting Abstract

    Patel, P.; Ruppert, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; Schiller, G. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Allogeneic transplantation in fit older adults is feasible and encouragingly efficacious. Post remission data from the prospective ECOG-ACRIN (E2906) clinical study
    Meeting Abstract

    Ofran, Y.; Sun, Z.; Rowe, J. M.; Claxton, D. F.; Tallman, M. S.; Arber, D. A.; Melnick, A.; Levine, R. L.; Paietta, E.; Godwin, J. E.; more...
    Blood (2021)

    Fulltext@MSK | Save